The IL-17 signaling pathway is considered to be highly upregulated in the inflammatory tissues of patients with autoimmune diseases [31–33], and IL-17-specific antibody treatments are remarkably effective for treating certain inflammatory diseases, such as Crohn's disease [34–36]. Here, IL17A is linked to Crohn disease.